17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

This study has been completed.

Study NCT00103272 Information provided by National Cancer Institute (NCI)

First Received: February 7, 2005 Last Updated: February 6, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	April 2008 (Final data collection date for primary outcome measure)